Contribution of ECT2 to Tubulointerstitial Fibrosis in the Progression of Chronic Kidney Disease

Kai-Xin Song1, Hua Su2

  • 1Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Current Medical Science
|October 26, 2024
PubMed
Abstract

Insights

Epithelial cell transforming sequence 2 (ECT2) is a key mediator in chronic kidney disease (CKD) development and progression, particularly in tubulointerstitial fibrosis. This study identified ECT2 as a novel therapeutic target for CKD.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Genetics

Background:

  • Chronic kidney disease (CKD) pathogenesis is complex and poorly understood, hindering effective treatments.
  • Identifying novel mediators is crucial for developing new therapeutic strategies for CKD.

Purpose of the Study:

  • To identify novel mediators contributing to the development of chronic kidney disease (CKD).
  • To investigate the role of Epithelial cell transforming sequence 2 (ECT2) in kidney fibrosis and CKD progression.

Main Methods:

  • Utilized bioinformatics databases (ClinVar, STRING, MEME Suite, TRRUST, GEO) and R Studio for gene analysis.
  • Employed transcriptomic analysis, immunohistochemistry, qRT-PCR, and Western blotting for validation.
  • Conducted in vitro experiments using HK-2 cells and in vivo studies with a unilateral ureteral obstruction (UUO) mouse model.

Main Results:

  • Identified 26 potential CKD disease genes, including Epithelial cell transforming sequence 2 (ECT2), cyclin B 1, caspase 7, and collagen alpha-1 (IV).
  • ECT2 expression was significantly elevated in CKD patient kidney tissue and upregulated in TGF-β1-treated HK-2 cells.
  • ECT2 overexpression or knockdown modulated fibrosis markers in HK-2 cells, confirming its role in kidney fibrosis.

Conclusions:

  • Epithelial cell transforming sequence 2 (ECT2) plays a significant role in the development and progression of CKD.
  • ECT2 is particularly associated with tubulointerstitial fibrosis, suggesting it as a potential therapeutic target.